PsyMed Ventures Newsletter

Share this post

Palo Santo’s $35M fund investing in the future of psychedelic therapeutics

psymedventures.substack.com

Palo Santo’s $35M fund investing in the future of psychedelic therapeutics

Business Trip, a podcast about psychedelic entrepreneurship

PsyMed Ventures
Mar 21, 2022
1
Share this post

Palo Santo’s $35M fund investing in the future of psychedelic therapeutics

psymedventures.substack.com

Welcome back to Business Trip, a podcast about psychedelic entrepreneurship! 🍄

In Episode 16, we chat with Tim Schlidt, a partner at Palo Santo which is a $35M fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis, Tactogen, and Journey Clinical.

In this episode, we discuss:

  • Tim’s background in healthcare finance 

  • Investing in classic psychedelic compounds vs. 2nd generation compounds

  • Hallmarks of a good first meeting with a prospective investment

Listen to the episode here, on Spotify or Apple Podcasts.

When you’re done listening, tweet at us @businesstripfm to share your thoughts!


About Us

Business Trip tells the story of the emerging industry of psychedelics. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem. 

Business Trip is produced by Greg Kubin and Matias Serebrinsky — we’re advocates of the healing powers of psychedelic medicine and see a bright future ahead for the industry.

Thanks for listening,

Matias and Greg

💖 Know someone who would enjoy Business Trip?

Follow us on Twitter & Instagram.

Share this post

Palo Santo’s $35M fund investing in the future of psychedelic therapeutics

psymedventures.substack.com
Comments
TopNewCommunity

No posts

Ready for more?

© 2023 Business Trip
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing